摘要 |
The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable tautomers, salts, or stereoisomers thereof which are inhibitors of Spleen tyrosine kinase (syk) and/or Janus (JAK) kinases. Also disclosed are intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk and/or JAK kinase activity, methods of inhibition the platelet aggregation. These compounds are suitable for treating a number of conditions mediated at least in part by syk and/or JAK kinase activity, such as cardiovascular disease, inflammatory disease, autoimmune disease and cell proliferative disorder, thrombosis, allergy, asthma, rheumatoid arthritis, leukemia, or non-Hodgkin's lymphoma.
|